Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
PRAXthis companyPraxis Precision Medicines, Inc.	$302.94	-21.86×	7.55×	0×	-20.7×	-94.6%	0.0%	0.0%	0.0%	-34.5%	-37.1%	-3.8%	0×	1.18×	0×	10.22×	0.0%	2	96.13	2	C
ACADAcadia Pharmaceuticals Inc.	$21.38	11.51×	3.69×	4.22×	29.19×	-252.2%	91.7%	9.8%	36.5%	31.9%	8.1%	2.3%	0.04×	-0.83×	0×	3.83×	0.0%	4	4.87	4	A-
AVXLAnavex Life Sciences Corp.	$1.22	-16.48×	8×	0×	-14.16×	2.3%	0.0%	0.0%	0.0%	-48.9%	-54.2%	-5.1%	0×	2.21×	0×	11.6×	0.0%	1	4.27	2	C
AXSMAxsome Therapeutics, Inc.	$131.62	-49.63×	102.9×	14.23×	-53.57×	-423.3%	92.6%	-26.5%	-28.7%	-207.5%	-44.0%	-1.0%	2.73×	0.49×	-25.81×	1.55×	0.0%	3	4.25	1	D+
DNLIDenali Therapeutics Inc.	$19.98	-5.56×	2.86×	0×	-5.48×	-94.9%	0.0%	0.0%	0.0%	-50.6%	-52.6%	-14.6%	0.04×	0.34×	0×	9.16×	0.0%	3	2.05	2	C
NBIXNeurocrine Biosciences, Inc.	$166.33	29.49×	4.34×	4.93×	20.72×	140.9%	98.2%	21.6%	16.7%	14.7%	10.8%	5.3%	0.13×	-0.45×	0×	3.39×	0.0%	5	6.69	4	A
Peer median	—	-5.56×	4.34×	4.22×	-5.48×	-94.9%	91.7%	0.0%	0.0%	-48.9%	-44.0%	-1.0%	0.04×	0.34×	0×	3.83×	0.0%	3	4.27	2	—